Table 4

Associations of breast cancer with combined IGF and steroid hormones among premenopausal womena

VariableIGF-IIGF-IIIGFBP-3
No.bOR (95% CI)No.OR (95% CI)No.OR (95% CI)
Testosterone
 Low/lowc41/331.0036/321.0035/261.00
 High/low44/320.97 (0.49–1.88)49/561.23 (0.65–2.31)50/300.84 (0.40–1.79)
 Low/high44/391.13 (0.57–2.24)49/400.64 (0.25–1.66)50/461.54 (0.74–3.21)
 High/high41/672.50 (1.25–5.01)36/431.19 (0.50–2.83)35/693.31 (1.53–7.17)
Estrone
 Low/low43/281.0037/371.0041/271.00
 High/low42/371.21 (0.61–2.40)47/501.04 (0.55–1.99)44/290.84 (0.42–1.68)
 Low/high41/411.50 (0.77–2.93)47/320.58 (0.25–1.33)43/421.48 (0.69–3.18)
 High/high43/642.30 (1.21–4.37)38/511.17 (0.52–2.66)41/723.32 (1.61–6.82)
Estradiol
 Low/low47/321.0039/551.0044/321.00
 High/low38/331.12 (0.60–2.08)46/330.47 (0.26–0.87)41/240.72 (0.36–1.40)
 Low/high38/612.39 (1.27–4.47)46/380.44 (0.18–1.03)41/612.24 (1.17–4.29)
 High/high47/451.44 (0.76–2.73)39/450.72 (0.30–1.70)44/612.19 (1.07–4.46)
Estrone-S
 Low/low40/291.0026/311.0039/361.00
 High/low45/361.16 (0.60–2.25)59/570.91 (0.46–1.81)46/200.59 (0.29–1.21)
 Low/high45/561.86 (0.96–3.63)59/540.75 (0.34–1.66)46/491.53 (0.78–2.99)
 High/high40/501.97 (1.02–3.82)26/290.94 (0.38–2.36)39/663.00 (1.40–6.44)
DHEA-S
 Low/low45/351.0036/351.0032/291.00
 High/low40/300.96 (0.50–1.85)49/531.17 (0.63–2.18)53/270.61 (0.30–1.26)
 Low/high40/391.37 (0.73–2.56)49/390.76 (0.33–1.78)53/451.21 (0.57–2.56)
 High/high45/672.25 (1.18–4.29)36/441.11 (0.47–2.63)32/702.92 (1.37–6.20)
  • a Unadjusted conditional logistic regression analysis.

  • b Number of control versus number of case.

  • c Low/low, low steroids and low IGF-I or IGFBP-3; High/low, high steroids and low IGF-I or IGFBP-3; Low/high, low steroids and high IGF-I or IGFBP-3; High/high, high steroids and high IGF-I or IGFBP-3; Low, lower than median; High, higher than or equal to median.